David M Goldenberg Net Worth

The estimated Net Worth of David M Goldenberg is at least $497 million dollars as of 28 February 2018. David Goldenberg owns over 117,729 units of Immunomedics stock worth over $493,180,321 and over the last 20 years David sold IMMU stock worth over $4,100,862.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Goldenberg IMMU stock SEC Form 4 insiders trading

David has made over 12 trades of the Immunomedics stock since 2005, according to the Form 4 filled with the SEC. Most recently David sold 117,729 units of IMMU stock worth $2,049,662 on 28 February 2018.

The largest trade David's ever made was selling 500,000 units of Immunomedics stock on 3 June 2005 worth over $1,000,000. On average, David trades about 61,818 units every 116 days since 2004. As of 28 February 2018 David still owns at least 5,613,252 units of Immunomedics stock.

You can see the complete history of David Goldenberg stock trades at the bottom of the page.

What's David Goldenberg's mailing address?

David's mailing address filed with the SEC is C/O IMMUNOMEDICS INC, 300 AMERICAN RD, MORRIS PLAINS, NJ, 07950.

Insiders trading at Immunomedics

Over the last 21 years, insiders at Immunomedics have traded over $5,318,095 worth of Immunomedics stock and bought 12,330,539 units worth $195,802,181 . The most active insiders traders include Capital Advisors Llc Aghaza..., David M Goldenberg et Cynthia L Goldenberg. On average, Immunomedics executives and independent directors trade stock every 105 days with the average trade being worth of $27,159,459. The most recent stock trade was executed by Barbara Gayle Duncan on 14 September 2020, trading 2,500 units of IMMU stock currently worth $42,400.

What does Immunomedics do?

Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Complete history of David Goldenberg stock trades at Immunomedics

Immunomedics executives and stock owners

Immunomedics executives and other stock owners filed with the SEC include:

• Behzad Avoro Capital Adviso...,
  
• Geoffrey F Cox,
  Director
• Robert Forrester,
  Director
• Jason Aryeh,
  Director
• Harout Semerjian,
  President and CEO
• Bob Oliver,
  Director
• Marvin Jaffe,
  Director
• Michael F. Pehl,
  President and CEO
• Capital Advisors Llc Aghaza...,
  
• Peter Barton Hutt,
  Director
• Scott A Canute,
  Director
• Khalid Islam,
  Director
• Michael Garone,
  CHIEF FINANCIAL OFFICER
• Brian A Markison,
  Director
• Behzad Aghazadeh,
  Director
• Select Advisor Llc Ven Bio,
  Director
• Robert Iannone,
  CHIEF MEDICAL OFFICER
• William Fricker,
  Principal Accounting Officer
• Morris Rosenberg,
  Chief Technology Officer
• Charles M Baum,
  Director
• Bryan Ball,
  Chief Quality Officer
• Barbara Gayle Duncan,
  Director
• Kurt J. Andrews,
  Chief Human Resources Officer
• Ivan D Horak,
  EVP R&D & Ch. Scientific Off.
• Cynthia L Goldenberg,
  President and CEO
• Richard R Pivirotto,
  Director
• Don C Stark,
  Director
• Mary E Paetzold,
  Director
• Arthur S Kirsch,
  Director
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Richard L. Sherman,
  Director
• David M Goldenberg,
  Chairman & Ch. Strategic Off.
• Marcella Lo Castro,
  Director
• Edward T Wolynic,
  Director
• Morton Coleman,
  Director
• Gerard G Gorman,
  VP of Finance & CFO
• Kenneth J Zuerblis,
  Director
• Lorettta M Itri,
  Chief Medical Officer
• Robert Azelby,
  Director
• Usama Malik,
  Chief Fin. & Business Officer
• Brendan Delaney,
  Chief Commercial Officer
• Jared Freedberg,
  Gen. Counsel & Corp. Secretary